JY
TLSI icon

Jeff Yass’s TriSalus Life Sciences TLSI Stock Holding History

Jeff Yass’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,994
Closed -$52K – 14533
2026
Q1 		$52K Buy
+12,994
New +$63.6K ﹤0.01% 12629
2025
Q3 		– Sell
-20,558
Closed -$112K – 13886
2025
Q2 		$112K Buy
+20,558
New +$110K ﹤0.01% 11715

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Jeff Yass's TLSI Position: Q2 2026 in Review

Jeff Yass sold out of TriSalus Life Sciences (TLSI) in Q2 2026, closing a stake of 12,994 shares — an estimated $52K sold.

Jeff Yass first reported a position in TLSI in Q2 2025 and held it in 2 quarters. The position peaked at $112K in Q2 2025. 78 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • Jeff Yass reported no remaining TriSalus Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 12,994 TriSalus Life Sciences shares in Q2 2026, an estimated $52K.
  • Jeff Yass first reported a position in TriSalus Life Sciences in Q2 2025 and held it in 2 quarters.
  • Jeff Yass's TriSalus Life Sciences position peaked at $112K in Q2 2025.
  • 78 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.